Insider Selling: iRadimed (NASDAQ:IRMD) Director Sells $122,615.79 in Stock

iRadimed Corporation (NASDAQ:IRMD) Director Monty Allen sold 1,419 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $86.41, for a total value of $122,615.79. Following the sale, the director owned 19,581 shares in the company, valued at approximately $1,691,994.21. This represents a 6.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

iRadimed Trading Down 2.0%

NASDAQ:IRMD opened at $81.87 on Friday. iRadimed Corporation has a 1-year low of $67.84 and a 1-year high of $107.90. The firm has a fifty day simple moving average of $91.10 and a 200 day simple moving average of $93.09. The stock has a market capitalization of $1.05 billion, a PE ratio of 45.74 and a beta of 0.89.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.02. The firm had revenue of $20.47 million for the quarter, compared to analyst estimates of $20.35 million. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, equities analysts predict that iRadimed Corporation will post 1.98 earnings per share for the current fiscal year.

iRadimed Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, August 28th. Stockholders of record on Friday, August 14th were issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend was Friday, August 14th. iRadimed’s dividend payout ratio is presently 44.69%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on IRMD shares. Weiss Ratings upgraded shares of iRadimed from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. Wall Street Zen downgraded iRadimed from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, iRadimed has an average rating of “Buy” and a consensus price target of $120.00.

Hedge Funds Weigh In On iRadimed

Several institutional investors and hedge funds have recently modified their holdings of IRMD. Rice Hall James & Associates LLC acquired a new stake in shares of iRadimed during the second quarter worth $2,909,000. Hsbc Holdings PLC acquired a new position in shares of iRadimed during the 2nd quarter worth approximately $1,130,000. Bridge City Capital LLC increased its holdings in shares of iRadimed by 19.4% during the fourth quarter. Bridge City Capital LLC now owns 70,854 shares of the medical equipment provider’s stock worth $6,893,000 after purchasing an additional 11,509 shares during the period. Baader Bank Aktiengesellschaft acquired a new stake in shares of iRadimed in the fourth quarter valued at approximately $595,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of iRadimed in the second quarter valued at approximately $7,252,000. 92.34% of the stock is currently owned by institutional investors and hedge funds.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.